title: Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group.
abstract: OBJECTIVE
  To study the safety and efficacy of aerosolized recombinant human DNase I in the treatment of idiopathic bronchiectasis.
  
  
  METHODS
  Double-blind, randomized, placebo-controlled, multicenter study.
  
  
  METHODS
  Three hundred forty-nine adult outpatients in stable condition with idiopathic bronchiectasis from 23 centers in North America, Great Britain, and Ireland.
  
  
  METHODS
  Study patients received aerosolized rhDNase or placebo twice daily for 24 weeks. Primary end points were incidence of pulmonary exacerbations and mean percent change in FEV1 from baseline over the treatment period.
  
  
  RESULTS
  Pulmonary exacerbations were more frequent and FEV1 decline was greater in patients who received rhDNase compared with placebo during this 24-week trial.
  
  
  CONCLUSIONS
  rhDNase was ineffective and potentially harmful in this group of adult outpatients in stable condition with idiopathic bronchiectasis. This contrasts with previously published results that demonstrated efficacy of rhDNase in patients with cystic fibrosis bronchiectasis.
authors.affiliation: Division of Pulmonary Medicine, Georgetown University Medical Center, Washington, DC, USA.
authors.forename: A E
authors.initials: AE
authors.lastname: O'Donnell
authors.forename: A F
authors.initials: AF
authors.lastname: Barker
authors.forename: J S
authors.initials: JS
authors.lastname: Ilowite
authors.forename: R B
authors.initials: RB
authors.lastname: Fick
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols; D001987:Bronchiectasis / Q000188:drug therapy*; D003850:Deoxyribonuclease I / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005100:Expectorants / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013147:Spirometry; D013997:Time Factors; D017211:Treatment Failure
chemical_list: D000336:Aerosols; D005100:Expectorants; D011994:Recombinant Proteins; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I